ArticleWorld journal of surgical oncology2025
High expression of polo-like kinase 4 predicts worse progression-free survival in diffuse large B cell lymphoma patients treated with R-CHOP.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPolo-like kinase 4 (PLK4) has been shown to be a tumor-promoting factor with multiple impacts on cancer growth, invasiveness, and treatment sensitivity. The current study aimed to investigate the expression of PLK4 in diffuse large B-cell lymphoma (DLBCL) versus control tissues and its relationship with disease features and prognosis in DLBCL patients undergoing R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) treatment.
methodsNinety-seven DLBCL patients who received R-CHOP treatment were retrospectively included, and the lesion tissue was retrieved and subjected to quantitative polymerase chain reaction (qPCR) for PLK expression determination. Another 30 control tissues (reactive lymphoid tissue) were also subjected to qPCR.
resultsPLK4 expression was greater in DLBCL tissue than in reactive lymphoid tissue (nearly 3-fold change, P < 0.001). PLK4 in DLBCL was correlated with increased Ann Arbor stage (P = 0.038), lactate dehydrogenase abnormality (P = 0.031), international prognostic index (IPI) score (P = 0.002) and IPI risk stratification (P = 0.001). After cutoff by quartiles, PLK4 ≥ 50% quantile (P = 0.040) and PLK4 ≥ 75% quantile (P = 0.021) were correlated with shorter progression-free survival (PFS), but PLK4 ≥ 25% quantile was not (P = 0.236); PLK4 ≥ 25% quantile (P = 0.349), PLK4 ≥ 50% quantile (P = 0.126), and PLK4 ≥ 75% quantile (P = 0.090) were not correlated with overall survival (OS). Moreover, threshold by best cutoff value (3.755), PLK4 > 3.755 was correlated with both worse PFS (P = 0.002) and OS (P = 0.036). After adjustment via multivariate Cox regression, PLK4 > 3.755 was independently correlated with PFS (hazard ratio = 3.900, P = 0.023).
conclusionsHigh PLK4 expression can reflect severe disease conditions and predict poor PFS in DLBCL patients undergoing R-CHOP treatment. This study sheds a light on the potency of PLK4 as a prognostic biomarker for DLBCL management. However, more large-sample-sized and multiple regional studies are needed for verification in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.